PTI-1

PTI-1

Systematic (IUPAC) name
N,N-diethyl-N-((2-(1-pentyl-1H-indol-3-yl)thiazol-4-yl)methyl)ethanamine
Clinical data
Legal status	CA: Schedule II
Identifiers
CAS Number	1400742-46-2
Chemical data
Formula	C21H29N3S
Molar mass	355.54 g/mol
SMILES CCCCCN1C=C(C2=NC(CN(CC)CC)=CS2)C3=CC=CC=C31.Cl
InChI InChI=1S/C21H29N3S.ClH/c1-4-7-10-13-24-15-19(18-11-8-9-12-20(18)24)21-22-17(16-25-21)14-23(5-2)6-3;/h8-9,11-12,15-16H,4-7,10,13-14H2,1-3H3;1H Key:NPYOTZAJIONLKZ-UHFFFAOYSA-N

PTI-1 is an indole-based synthetic cannabinoid.^[1] It is one of few synthetic cannabinoids containing a thiazole group and is closely related to PTI-2. These compounds may be viewed as simplified analogues of indole-3-heterocycle compounds originally developed by Organon and subsequently further researched by Merck.^[2][3][4][5]

See also

• JWH-018
• LBP-1 (drug)
• PTI-2

References

1. "PTI-1". Cayman Chemical. Retrieved 8 July 2015.
2. Julia Adam-Worrall, et al. (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor. Patent US 7700634, priority date 5 March 2004
3. Paul David Ratcliffe, et al. Indole Derivatives. Patent US 7763732, priority date 24 August 2005
4. Julia Adam, et al. Indole Derivatives. Patent WO 2008/101995, priority date 22 February 2007
5. Takao Kiyoi, et al. Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists. Bioorganic and Medicinal Chemistry Letters 2011; 21(6):1748-1753. doi: 10.1016/j.bmcl.2011.01.082